Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease
Andrew M Wilson, David S Shin, Carlton Weatherby, Randall K Harada, Martin K Ng, Nandini Nair, Jan Kielstein, John P Cooke
VASCULAR MEDICINE | SAGE PUBLICATIONS LTD | Published : 2010
Peripheral arterial disease (PAD) is associated with major cardiovascular morbidity and mortality. Abnormalities in nitric oxide metabolism due to excess of the NO synthase inhibitor asymmetric dimethylarginine (ADMA) may be pathogenic in PAD. We explored the association between ADMA levels and markers of atherosclerosis, function, and prognosis. A total of 133 patients with symptomatic PAD were enrolled. Ankle-brachial index (ABI), walking time, vascular function measures (arterial compliance and flow-mediated vasodilatation) and plasma ADMA level were assessed for each patient at baseline. ADMA correlated inversely with ABI (r = -0.238, p = 0.003) and walking time (r = -0.255, p = 0.001), ..View full abstract
Awarded by National Institutes of Health
Awarded by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
This study was supported by grants from the National Institutes of Health (RO1 HL-75774, R21 HL085743, and K12 HL087746), and by the NIH Clinical and Translational Science Award. Dr Cooke is the inventor of patents owned by Stanford University for diagnostic and therapeutic applications of the NOS pathway from which he receives royalties.